Sunday, July 20, 2025 7/20/2025

Investigating the impact of chromosomal instability on prostate cancer aggressiveness

Award Number: R01CA294563
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/08/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Investigating the impact of chromosomal instability on prostate cancer aggressiveness - PROJECT SUMMARY Prostate cancer (PC) is a leading cause of male cancer-related deaths. Once disseminated PC is incurable as it gradually progresses to all therapeutic options. The mechanisms underlying aggressive features and lethality of metastatic PC remain an unmet clinical need. We and others have reported that metastatic PC displays the highest levels of chromosomal instability (CIN), and we have shown that transcriptional reprogramming allows PC CIN-adaptation and survival in advanced disease. Yet, the molecular underpinnings of CIN impact on PC remain poorly understood. Using genetic, proteomic, epigenomics and high-resolution microscopy, we found that CIN is linked to transcriptional rewiring and bookmarking suggesting a role of CIN in cell reprogramming in lethal PC. High CIN PC remains highly dependent on mitotic fidelity programs like the ones controlled by MASTL kinase to restrain lethal catastrophic CIN levels. We find that MASTL regulates new late mitotic processes involved in centrosome biology and cytokinesis in PC cells. However, the substrates and effectors by which MASTL regulate these functions remain unknown. Finally, our in vivo data strongly suggest a relevant role of CIN impacting anti- tumor immunity in PC. In this application we will use unique genetic models to identify the substrates and cofactors by which MASTL kinase regulates new functions in high CIN PC (Aim 1). We will investigate the molecules and mechanisms underlying CIN-induced transcriptional reprogramming and gene bookmarking in PC (Aim 2) and will explore the tumor immune cell intrinsic and extrinsic mechanisms triggered by CIN in PC that may enhance immunotherapy efficacy (Aim 3). Through these studies we will mechanistically uncover novel aspects of CIN consequences for PC and may identify new potential treatment strategies for this lethal disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $485,354 )
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Cause and Prevention Research	000	2	5/19/2025	NON-COMPETING CONTINUATION	$485,354
														Subtotal = $485,354

Issue Date FY: 2024 ( Subtotal = $485,354 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Cause and Prevention Research	000	1	7/5/2024	NEW	$485,354
														Subtotal = $485,354

Grand Total All Awards = $970,708

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating the impact of chromosomal instability on prostate cancer aggressiveness

Award Number: R01CA294563

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/08/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer